Solid Tumor Program

The Solid Tumor Program at Texas Children's Cancer Center provides state-of-the-art clinical care for children with tumors of the bone, soft tissue, abdomen and other areas. This comprehensive program provides a multidisciplinary team of experts who collaborate in the care of each patient and the development and execution of cutting-edge clinical trials to improve outcomes for these patients.

Investigators from Texas Children's Solid Tumor Program play major leadership roles at the national level through participation in the solid tumor clinical research efforts of the National Cancer Institute-sponsored Children's Oncology Group. Among the many clinical trials underway at Texas Children's Cancer Center are those exploring the use of:

  • Gene therapy for retinoblastoma, a tumor of the eye, using an adenovirus to deliver a gene that conveys tumor sensitivity to ganciclovir, a common antiviral medication
  • Risk-based therapy for children and young adults with osteosarcoma, the most common bone tumor in children
  • New strategies for the treatment of neuroblastoma.

The Solid Tumor team also has extensive expertise in the treatment of rare tumors, such as hepatoblastoma and hepatocellular carcinoma (liver tumors), germ cell tumors (tumors of the reproductive organs), sarcomas of the soft tissues, and many other cancers. In addition, the Solid Tumor team has a special interest in the study of vascular tumors (hemangiomas, vascular malformations and malignancies).



Page modified on December 27, 2021